Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 2Xanthogranuloma, Juvenile 1Wilms Tumor 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Ovarian Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Nerve Sheath Neoplasms 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Inhibition, Psychological 1Histiocytosis, Langerhans-Cell 1Histiocytic Sarcoma 1Hepatoblastoma 1Glioma 1Ependymoma 1Central Nervous System Neoplasms 1

Interventions

tazemetostat 1selinexor 1pazopanib 1Proton Therapy 1Nivolumab 1Ipilimumab 1Ifosfamide 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Nerve Sheath Neoplasms × tazemetostat × 30 days × Clear all
NCT04917042 2026-06-04

Tazemetostat in Malignant Peripheral Nerve Sheath Tumors

University of Florida

Phase 2 Active not recruiting
10 enrolled 12 charts
Sarcoma

Inhibition, Psychological, Sarcoma, Nerve Sheath Neoplasms, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡